Tert (telomerase reverse transcriptase) - Rat Genome Database

Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Tert (telomerase reverse transcriptase) Rattus norvegicus
Analyze
Symbol: Tert
Name: telomerase reverse transcriptase
RGD ID: 70494
Description: Predicted to enable several functions, including chaperone binding activity; nucleic acid binding activity; and nucleotidyltransferase activity. Involved in several processes, including negative regulation of apoptotic process; positive regulation of transdifferentiation; and positive regulation of vascular associated smooth muscle cell migration. Located in mitochondrion and nucleus. Used to study chronic kidney disease and transient cerebral ischemia. Biomarker of hepatocellular carcinoma; pulmonary hypertension; and silicosis. Human ortholog(s) of this gene implicated in several diseases, including autosomal dominant dyskeratosis congenita 2; carcinoma (multiple); gastrointestinal stromal tumor; leukemia (multiple); and melanoma (multiple). Orthologous to human TERT (telomerase reverse transcriptase); PARTICIPATES IN hypoxia inducible factor pathway; INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: telomerase catalytic subunit
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Allele / Splice: Tertem2Mcwi  
Genetic Models: WKY-Tertem2Mcwi
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2129,637,213 - 29,659,509 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl129,637,506 - 29,659,561 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx129,439,189 - 29,459,951 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0135,439,034 - 35,459,796 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0129,639,816 - 29,660,578 (-)NCBIRnor_WKY
Rnor_6.0132,250,876 - 32,275,330 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl132,251,714 - 32,272,476 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0133,675,744 - 33,697,542 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4130,445,180 - 30,465,942 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera128,286,050 - 28,306,805 (-)NCBICelera
Cytogenetic Map1p11NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adrenocortical carcinoma  (ISO)
Alcoholic Liver Diseases  (ISO)
aplastic anemia  (ISO)
Autosomal Dominant Dyskeratosis Congenita  (ISO)
autosomal dominant dyskeratosis congenita 1  (ISO)
autosomal dominant dyskeratosis congenita 2  (ISO)
autosomal recessive dyskeratosis congenita 1  (ISO)
autosomal recessive dyskeratosis congenita 4  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
basal cell carcinoma  (ISO)
beta thalassemia  (ISO)
brain cancer  (ISO)
Brain Hypoxia-Ischemia  (IDA)
breast cancer  (ISO)
breast carcinoma  (ISO)
Breast Neoplasms  (ISO)
cervix uteri carcinoma in situ  (ISO)
Chronic Hepatitis B  (ISO)
chronic kidney disease  (IDA)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (ISO)
chronic recurrent multifocal osteomyelitis  (ISO)
colon adenocarcinoma  (ISO)
coronary artery disease  (ISO)
Coronary Disease  (ISO)
Cri-du-Chat syndrome  (ISO)
Cutaneous Malignant Melanoma, Susceptibility To, 1  (ISO)
Diabetic Cardiomyopathies  (IEP)
disease of cellular proliferation  (ISO)
Disease Progression  (ISO)
ductal carcinoma in situ  (ISO)
dyskeratosis congenita  (ISO)
Endometrial Neoplasms  (ISO)
esophageal atresia  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (IEP)
Experimental Melanoma  (ISO)
familial melanoma  (ISO)
fibrosarcoma  (ISO)
gallbladder carcinoma  (ISO)
gastrointestinal stromal tumor  (ISO)
Genetic Predisposition to Disease  (ISO)
hepatitis C  (ISO)
hepatocellular carcinoma  (IEP,ISO)
hepatocellular clear cell carcinoma  (ISO)
hereditary breast ovarian cancer syndrome  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
high grade glioma  (ISO)
Hoyeraal Hreidarsson Syndrome  (ISO)
idiopathic pulmonary fibrosis  (ISO)
interstitial lung disease  (ISO)
kidney disease  (ISO)
leiomyosarcoma  (ISO)
Liver Neoplasms  (ISO)
Liver Reperfusion Injury  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphoid leukemia  (ISO)
macrocytic anemia  (ISO)
melanoma  (ISO)
microcephaly  (ISO)
multiple myeloma  (ISO)
myelodysplastic syndrome  (ISO)
myeloid neoplasm  (ISO)
nasopharynx carcinoma  (ISO)
nephroblastoma  (ISO)
neuroblastoma  (ISO)
Nonimmune Chronic Idiopathic Neutropenia, Adult  (ISO)
oral squamous cell carcinoma  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic cancer  (ISO)
Parkinsonism-Dystonia, Infantile  (ISO)
plasma cell leukemia  (ISO)
primary immunodeficiency disease  (ISO)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 1  (ISO)
pulmonary hypertension  (IEP,ISO)
Refractory Anemia  (ISO)
Refractory Anemia with Excess of Blasts  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (ISO)
silicosis  (IEP)
small cell carcinoma  (ISO)
Spinal Cord Injuries  (IEP,ISO)
stomach cancer  (ISO)
systemic lupus erythematosus  (ISO)
teratoma  (ISO)
Thyroid Neoplasms  (ISO)
transient cerebral ischemia  (IDA)
transitional cell carcinoma  (ISO)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)
Uterine Neoplasms  (ISO)
viral hepatitis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-schisandrin B  (EXP)
(-)-demecolcine  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(R,R,R)-alpha-tocopherol  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-(5-isoquinolinesulfonyl)-2-methylpiperazine  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
3',5'-cyclic AMP  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3-aminobenzamide  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid  (ISO)
4-hydroperoxycyclophosphamide  (ISO)
5-(2-methylpiperazine-1-sulfonyl)isoquinoline  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
5-fluorouracil  (ISO)
9-cis-retinoic acid  (ISO)
abacavir  (ISO)
acetamide  (EXP)
acetic acid  (ISO)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
aflatoxin B1  (EXP,ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-pinene  (ISO)
ammonium chloride  (EXP)
anilines  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antirheumatic drug  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
azoxystrobin  (ISO)
benzamide  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[e]pyrene  (ISO)
berberine  (ISO)
bicalutamide  (ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (ISO)
Boldine  (ISO)
bromochloroacetic acid  (ISO)
bucladesine  (ISO)
cadmium dichloride  (EXP)
calcitriol  (ISO)
camptothecin  (ISO)
carbon nanotube  (ISO)
carmustine  (ISO)
chelidonine  (ISO)
chlorpyrifos  (EXP)
choline  (ISO)
cisplatin  (ISO)
citric acid  (ISO)
copper(II) sulfate  (ISO)
Cuprizon  (EXP)
curcumin  (ISO)
D-glucose  (ISO)
deguelin  (ISO)
diarsenic trioxide  (ISO)
dibenziodolium  (ISO)
dibenzoylmethane  (ISO)
dicrotophos  (ISO)
dimethyl sulfoxide  (ISO)
disodium selenite  (ISO)
doxorubicin  (ISO)
elemental selenium  (EXP,ISO)
ellagic acid  (EXP,ISO)
endosulfan  (ISO)
ethanol  (ISO)
ethyl methanesulfonate  (ISO)
fluorometholone  (ISO)
folic acid  (ISO)
fonofos  (ISO)
formaldehyde  (ISO)
fulvestrant  (ISO)
fumagillin  (EXP)
furan  (EXP)
gefitinib  (ISO)
genistein  (ISO)
glucose  (ISO)
glutathione  (ISO)
Honokiol  (ISO)
hydrogen peroxide  (ISO)
iprodione  (EXP)
iron atom  (EXP)
iron(0)  (EXP)
isothiocyanate  (ISO)
isotretinoin  (ISO)
L-ascorbic acid  (ISO)
letrozole  (ISO)
LY294002  (EXP,ISO)
mangiferin  (ISO)
manumycin A  (ISO)
medroxyprogesterone acetate  (ISO)
methapyrilene  (ISO)
mitomycin C  (ISO)
N-acetyl-L-cysteine  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
Nandrolone decanoate  (ISO)
Osajin  (ISO)
ozone  (ISO)
paclitaxel  (ISO)
parathion  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phosalone  (EXP)
picoxystrobin  (ISO)
platycodin D  (ISO)
Pomiferin  (ISO)
pterostilbene  (ISO)
puerarin  (ISO)
quercetin  (ISO)
raloxifene  (EXP,ISO)
reactive oxygen species  (ISO)
resveratrol  (ISO)
Rosavin  (ISO)
SB 203580  (ISO)
selenium atom  (EXP,ISO)
serpentine asbestos  (ISO)
silicate mineral  (EXP)
silicon dioxide  (ISO)
sirolimus  (ISO)
sodium arsenite  (ISO)
sodium dodecyl sulfate  (ISO)
sphingosine  (ISO)
stanozolol  (EXP)
staurosporine  (ISO)
succimer  (ISO)
sulforaphane  (ISO)
tamoxifen  (ISO)
temozolomide  (ISO)
terbufos  (ISO)
testosterone  (ISO)
tetrachloromethane  (EXP)
thioacetamide  (EXP)
Tomentosin  (ISO)
tributylstannane  (ISO)
trichostatin A  (ISO)
troglitazone  (ISO)
trovafloxacin  (ISO)
urethane  (ISO)
valproic acid  (ISO)
wortmannin  (ISO)
zidovudine  (ISO)
zinc dichloride  (ISO)
zinc oxide  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
cellular response to hypoxia  (IEP,ISO)
DNA biosynthetic process  (ISO)
DNA strand elongation  (ISO)
establishment of protein localization to telomere  (ISO)
mitochondrion organization  (ISO)
negative regulation of apoptotic process  (IMP)
negative regulation of cellular senescence  (ISO)
negative regulation of endothelial cell apoptotic process  (IDA)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand  (ISO)
negative regulation of gene expression  (ISO)
negative regulation of glial cell proliferation  (IDA)
negative regulation of neuron apoptotic process  (IMP)
negative regulation of siRNA production  (ISO)
positive regulation of angiogenesis  (IDA)
positive regulation of G1/S transition of mitotic cell cycle  (IMP)
positive regulation of glucose import  (ISO)
positive regulation of hair cycle  (ISO)
positive regulation of miRNA transcription  (ISO)
positive regulation of nitric-oxide synthase activity  (ISO)
positive regulation of protein binding  (ISO)
positive regulation of protein localization to nucleolus  (ISO)
positive regulation of stem cell proliferation  (ISO)
positive regulation of transdifferentiation  (IMP)
positive regulation of vascular associated smooth muscle cell migration  (IMP)
positive regulation of vascular associated smooth muscle cell proliferation  (IMP)
positive regulation of Wnt signaling pathway  (ISO)
regulation of protein stability  (ISO)
replicative senescence  (ISO)
response to cadmium ion  (IEP)
RNA biosynthetic process  (ISO)
RNA-templated DNA biosynthetic process  (IEA,ISO)
RNA-templated transcription  (ISO)
siRNA processing  (ISO)
siRNA transcription  (ISO)
telomere maintenance via telomerase  (IBA,ISO,ISS)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. CCDC26, CDKN2BAS, RTEL1 and TERT Polymorphisms in pediatric brain tumor susceptibility. Adel Fahmideh M, etal., Carcinogenesis. 2015 Aug;36(8):876-82. doi: 10.1093/carcin/bgv074. Epub 2015 May 25.
2. Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Arinaga M, etal., Ann Thorac Surg. 2000 Aug;70(2):401-5; discussion 405-6. doi: 10.1016/s0003-4975(00)01454-5.
3. Telomerase mutations in families with idiopathic pulmonary fibrosis. Armanios MY, etal., N Engl J Med. 2007 Mar 29;356(13):1317-26.
4. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). Azad AK, etal., Lung Cancer. 2014 Jun;84(3):289-94. doi: 10.1016/j.lungcan.2014.03.008. Epub 2014 Mar 13.
5. Telomere length and telomerase reverse transcriptase mRNA expression in patients with hepatitis C. Biron-Shental T, etal., Hepatogastroenterology. 2013 Oct;60(127):1713-6.
6. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Bock O, etal., Leuk Res. 2004 May;28(5):457-60.
7. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Briatore F, etal., Cancer Biol Ther. 2009 May;8(10):883-9. Epub 2009 May 8.
8. The role of TERT-CLPTM1L SNPs, hTERT expression and telomere length in the pathogenesis of oral squamous cell carcinoma. Carkic J, etal., J Oral Sci. 2016;58(4):449-458. doi: 10.2334/josnusd.16-0108.
9. TGF-beta induces telomerase-dependent pancreatic tumor cell cycle arrest. Cassar L, etal., Mol Cell Endocrinol. 2010 May 14;320(1-2):97-105. doi: 10.1016/j.mce.2010.02.002. Epub 2010 Feb 6.
10. Expression of telomerase subunits in gastric cancer. Chen F, etal., J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):741-3. doi: 10.1007/BF02896189.
11. Nuclear translocation of telomerase reverse transcriptase: a critical process in chemical induced hepatocellular carcinogenesis. Chen Y and Kong Q, Neoplasma. 2010;57(3):222-7.
12. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer. Chen Z, etal., Cancer Gene Ther. 2017 Jan;24(1):20-27. doi: 10.1038/cgt.2016.74. Epub 2016 Dec 16.
13. Evaluation of telomerase mRNA (hTERT) in childhood acute leukemia. Cogulu O, etal., Leuk Lymphoma. 2004 Dec;45(12):2477-80.
14. Effects of cadmium on telomerase activity, expressions of TERT, c-myc and P53, and apoptosis of rat hepatocytes. Dai W, etal., J Huazhong Univ Sci Technolog Med Sci. 2010 Dec;30(6):709-13. doi: 10.1007/s11596-010-0645-8. Epub 2010 Dec 22.
15. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Dasi F, etal., Ann N Y Acad Sci. 2006 Sep;1075:204-10.
16. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Domchek SM, etal., Cancer Res. 2007 Nov 1;67(21):10546-55.
17. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. Dome JS, etal., J Clin Oncol. 2005 Dec 20;23(36):9138-45. Epub 2005 Sep 19.
18. Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes. Dong W, etal., Leuk Res. 2014 Jul;38(7):830-5. doi: 10.1016/j.leukres.2014.04.008. Epub 2014 Apr 28.
19. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. Eissa S, etal., J Urol. 2007 Sep;178(3 Pt 1):1068-72. Epub 2007 Jul 20.
20. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
21. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Hara H, etal., Lung Cancer. 2001 Nov;34(2):219-26. doi: 10.1016/s0169-5002(01)00244-6.
22. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma. Huang W, etal., Oncotarget. 2017 Apr 18;8(16):26288-26297. doi: 10.18632/oncotarget.15458.
23. The effect on melanoma risk of genes previously associated with telomere length. Iles MM, etal., J Natl Cancer Inst. 2014 Sep 17;106(10). pii: dju267. doi: 10.1093/jnci/dju267. Print 2014 Oct.
24. TERT-rs33963617 and CLPTM1L-rs77518573 reduce the risk of non-small cell lung cancer in Chinese population. Ji Z, etal., Gene. 2020 Mar 20;731:144357. doi: 10.1016/j.gene.2020.144357. Epub 2020 Jan 11.
25. Expression of human telomerase reverse transcriptase and survivin gene in patients with myelodysplastic syndrome Jiao XL, etal., Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):294-8.
26. Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. Jung SW, etal., Hepatology. 2014 May;59(5):1912-20. doi: 10.1002/hep.26655. Epub 2014 Mar 27.
27. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia. Kim HJ, etal., Eur J Haematol. 2013 Nov;91(5):411-22. doi: 10.1111/ejh.12167. Epub 2013 Sep 18.
28. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Ko E, etal., Oncotarget. 2016 Jan 5;7(1):684-99. doi: 10.18632/oncotarget.6331.
29. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma. Kong SY, etal., J Cancer Res Clin Oncol. 2009 Aug;135(8):1091-8. doi: 10.1007/s00432-009-0549-9. Epub 2009 Jan 31.
30. Genetic variations in TERT-CLPTM1L genes and risk of lung cancer in Chinese women nonsmokers. Li C, etal., PLoS One. 2013 May 30;8(5):e64988. doi: 10.1371/journal.pone.0064988. Print 2013.
31. The neuroprotective role and mechanisms of TERT in neurons with oxygen-glucose deprivation. Li J, etal., Neuroscience. 2013 Nov 12;252:346-58. doi: 10.1016/j.neuroscience.2013.08.015. Epub 2013 Aug 19.
32. Expression of human telomerase reverse transcriptase in bone marrow CD34+ cells from patients with beta-thalassemia major. Li X, etal., Transfusion. 2008 Aug;48(8):1627-33. doi: 10.1111/j.1537-2995.2008.01724.x. Epub 2008 May 2.
33. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Liu J, etal., Int J Oncol. 2004 Apr;24(4):879-84.
34. Genetic variant in CLPTM1L confers reduced risk of lung cancer: a replication study in Chinese and a meta-analysis. Luo X, etal., Asian Pac J Cancer Prev. 2014;15(21):9241-7. doi: 10.7314/apjcp.2014.15.21.9241.
35. Telomere biology in cardiovascular disease - role of insulin sensitivity in diabetic hearts. Makino N, etal., Exp Clin Cardiol. 2010 Winter;15(4):e128-33.
36. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
37. Mechanisms of telomerase induction during vascular smooth muscle cell proliferation. Minamino T and Kourembanas S, Circ Res. 2001 Aug 3;89(3):237-43.
38. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Miura N, etal., Oncol Rep. 2007 Mar;17(3):541-8.
39. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Nault JC, etal., Hepatology. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372. Epub 2014 Oct 27.
40. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
41. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Novakovic S, etal., Oncol Rep. 2004 Jan;11(1):245-52.
42. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Oh H, etal., Proc Natl Acad Sci U S A 2001 Aug 28;98(18):10308-13.
43. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
44. Expression of telomerase reverse transcriptase mRNA and its quantitative analysis in human endometrial cancer. Oshita T, etal., Int J Oncol. 2000 Dec;17(6):1225-30.
45. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. Oya H, etal., Transplant Proc. 2006 Dec;38(10):3636-9. doi: 10.1016/j.transproceed.2006.10.172.
46. Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia. Pavlaki KI, etal., Haematologica. 2012 May;97(5):743-50. doi: 10.3324/haematol.2011.053983. Epub 2011 Dec 1.
47. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
48. Telomerase reverse transcriptase upregulation attenuates astrocyte proliferation and promotes neuronal survival in the hypoxic-ischemic rat brain. Qu Y, etal., Stroke. 2011 Dec;42(12):3542-50. doi: 10.1161/STROKEAHA.111.626325. Epub 2011 Sep 22.
49. Association of TERT polymorphisms with chronic hepatitis B in a Chinese Han population. Ren G, etal., Oncotarget. 2018 Jan 3;9(10):9199-9205. doi: 10.18632/oncotarget.23905. eCollection 2018 Feb 6.
50. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
51. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
52. Comprehensive gene review and curation RGD comprehensive gene curation
53. The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. Salhab M, etal., Breast Cancer Res Treat. 2007 Jul 7;.
54. Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. Satra M, etal., J Viral Hepat. 2007 Jan;14(1):41-7. doi: 10.1111/j.1365-2893.2006.00769.x.
55. Genetic variation in five genes important in telomere biology and risk for breast cancer. Savage SA, etal., Br J Cancer. 2007 Sep 17;97(6):832-6. Epub 2007 Aug 14.
56. Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Schrader M, etal., Oncol Rep. 2002 Sep-Oct;9(5):1097-105.
57. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. Sharma NK, etal., Nucleic Acids Res. 2012 Jan;40(2):712-25. doi: 10.1093/nar/gkr758. Epub 2011 Sep 21.
58. Positive feedback-loop of telomerase reverse transcriptase and 15-lipoxygenase-2 promotes pulmonary hypertension. Shen T, etal., PLoS One. 2013 Dec 23;8(12):e83132. doi: 10.1371/journal.pone.0083132. eCollection 2013.
59. TERT polymorphisms modify the risk of acute lymphoblastic leukemia in Chinese children. Sheng X, etal., Carcinogenesis. 2013 Jan;34(1):228-35. doi: 10.1093/carcin/bgs325. Epub 2012 Oct 11.
60. Silica inhalation altered telomere length and gene expression of telomere regulatory proteins in lung tissue of rats. Shoeb M, etal., Sci Rep. 2017 Dec 11;7(1):17284. doi: 10.1038/s41598-017-17645-y.
61. Angiogenic effect of endothelial progenitor cells transfected with telomerase reverse transcriptase on peritubular microvessel in five out of six subtotal nephrectomy rats. Shuai L, etal., Ren Fail. 2012;34(10):1270-80. doi: 10.3109/0886022X.2012.723592. Epub 2012 Sep 26.
62. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. Stefanou N, etal., BMC Cancer. 2010 Aug 19;10:442. doi: 10.1186/1471-2407-10-442.
63. Polymorphisms of TERT and CLPTM1L and the risk of hepatocellular carcinoma in Chinese males. Su LY, etal., Asian Pac J Cancer Prev. 2014;15(19):8197-201. doi: 10.7314/apjcp.2014.15.19.8197.
64. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. Takeda T, etal., J Clin Endocrinol Metab. 2003 Aug;88(8):3531-8.
65. Role of telomerase reverse transcriptase in glial scar formation after spinal cord injury in rats. Tao X, etal., Neurochem Res. 2013 Sep;38(9):1914-20. doi: 10.1007/s11064-013-1097-x. Epub 2013 Jun 22.
66. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Terrin L, etal., Leukemia. 2007 May;21(5):965-72. Epub 2007 Mar 8.
67. Significance of Insulin Signaling in Liver Regeneration Triggered by Portal Vein Ligation. Tseng JH, etal., J Surg Res. 2009 Jul 30.
68. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Ugel S, etal., Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.
69. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Ulaner GA, etal., Int J Cancer. 2000 Feb 1;85(3):330-5.
70. Telomere- and telomerase-interacting protein that unfolds telomere G-quadruplex and promotes telomere extension in mammalian cells. Wang F, etal., Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20413-8. doi: 10.1073/pnas.1200232109. Epub 2012 Nov 26.
71. High expression of human telomerase reverse transcriptase in high-grade intraepithelial neoplasia and carcinoma of uterine cervix and its correlation with human papillomavirus infection. Wang PH, etal., Reprod Sci. 2007 May;14(4):338-48.
72. Alleviating the ischemia-reperfusion injury of donor liver by transfection of exogenous hTERT genes. Wang W, etal., Transplant Proc. 2009 Jun;41(5):1499-503. doi: 10.1016/j.transproceed.2009.03.068.
73. [Expression of telomerase activity and its related genes in the marrow hemopoietic stem cells of children with aplastic anemia]. Wang XG, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2013 Jan;15(1):25-8.
74. Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Wang Y, etal., Carcinogenesis. 2010 Feb;31(2):234-8. doi: 10.1093/carcin/bgp287. Epub 2009 Dec 2.
75. [Expression of human telomerase reverse transcriptase in renal cell carcinoma and its clinical significance.] Wu P, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2008 Feb;28(2):272-4.
76. Telomerase reverse transcriptase acts in a feedback loop with NF-¿B pathway to regulate macrophage polarization in alcoholic liver disease. Wu XQ, etal., Sci Rep. 2016 Jan 4;6:18685. doi: 10.1038/srep18685.
77. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR. Xie XY, etal., Ann Clin Biochem. 2007 Nov;44(Pt 6):523-8.
78. Telomerase activity in plasma cell dyscrasias. Xu D, etal., Br J Cancer. 2001 Mar 2;84(5):621-5.
79. Improving recovery of spinal cord-injured rats by telomerase-driven human neural progenitor cells. Xu G, etal., Restor Neurol Neurosci. 2004;22(6):469-76.
80. Association of TERT-CLPTM1L and 8q24 Common Genetic Variants with Gallbladder Cancer Susceptibility and Prognosis in North Indian Population. Yadav S, etal., Biochem Genet. 2018 Aug;56(4):267-282. doi: 10.1007/s10528-018-9843-z. Epub 2018 Feb 15.
81. [Effects of cerebellar fastigial nucleus electrical stimulation on telomerase reverse transcriptase expression and mitochondrial apoptotic pathway in rats with focal cerebral ischemia and reperfusion]. Yang Y, etal., Zhonghua Yi Xue Za Zhi. 2011 Jun 21;91(23):1643-8.
82. TERT-CLPTM1L Rs401681 C>T polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Yin J, etal., PLoS One. 2014 Jul 9;9(7):e100667. doi: 10.1371/journal.pone.0100667. eCollection 2014.
83. Telomerase activity and expression of telomerase genes in squamous dysplasia and squamous cell carcinoma of the esophagus. Yu HP, etal., J Surg Oncol. 2004 May 1;86(2):99-104. doi: 10.1002/jso.20050.
84. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Yuan X, etal., Oncotarget. 2017 Apr 4;8(14):23120-23129. doi: 10.18632/oncotarget.15498.
85. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population. Zhang H, etal., Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):600-9. doi: 10.1016/j.clinre.2015.01.002. Epub 2015 Feb 13.
86. Genetic variations in the TERT and CLPTM1L gene region and gastrointestinal stromal tumors risk. Zhang R, etal., Oncotarget. 2015 Oct 13;6(31):31360-7. doi: 10.18632/oncotarget.5153.
87. Common variations in TERT-CLPTM1L locus are reproducibly associated with the risk of nasopharyngeal carcinoma in Chinese populations. Zhang Y, etal., Oncotarget. 2016 Jan 5;7(1):759-70. doi: 10.18632/oncotarget.6397.
88. Genetic variations in TERT-CLPTM1L genes and risk of lung cancer in a Chinese population. Zhao MM, etal., Asian Pac J Cancer Prev. 2014;15(6):2809-13. doi: 10.7314/apjcp.2014.15.6.2809.
89. Genetic variations in TERT-CLPTM1L locus are associated with risk of lung cancer in Chinese population. Zhong R, etal., Mol Carcinog. 2013 Nov;52 Suppl 1:E118-26. doi: 10.1002/mc.22043. Epub 2013 Jun 12.
90. The identification of two regulatory ESCC susceptibility genetic variants in the TERT-CLPTM1L loci. Zhou L, etal., Oncotarget. 2016 Feb 2;7(5):5495-506. doi: 10.18632/oncotarget.6747.
Additional References at PubMed
PMID:9398860   PMID:9443919   PMID:9454332   PMID:10197982   PMID:10449030   PMID:11313459   PMID:11432839   PMID:11701125   PMID:11927518   PMID:12135483   PMID:12632524   PMID:12729609  
PMID:12729792   PMID:13679242   PMID:14701760   PMID:15057822   PMID:15632080   PMID:15687494   PMID:16037417   PMID:16043710   PMID:16107853   PMID:16205635   PMID:16248892   PMID:16424384  
PMID:16454671   PMID:16507993   PMID:16785237   PMID:17456401   PMID:17940095   PMID:18082603   PMID:18818403   PMID:19567472   PMID:19571879   PMID:19701182   PMID:19751963   PMID:19855065  
PMID:20351177   PMID:20540267   PMID:20564349   PMID:20736004   PMID:20864668   PMID:21141566   PMID:21455098   PMID:21531765   PMID:21829167   PMID:22073357   PMID:22226966   PMID:22446191  
PMID:23193663   PMID:23450462   PMID:23474713   PMID:24415760   PMID:24882549   PMID:24970747   PMID:25156787   PMID:25569094   PMID:25589350   PMID:25662949   PMID:26194824   PMID:26505494  
PMID:27251157   PMID:29017189   PMID:29436610   PMID:29695869   PMID:30338789   PMID:33999989   PMID:34559580  


Genomics

Comparative Map Data
Tert
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2129,637,213 - 29,659,509 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl129,637,506 - 29,659,561 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx129,439,189 - 29,459,951 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0135,439,034 - 35,459,796 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0129,639,816 - 29,660,578 (-)NCBIRnor_WKY
Rnor_6.0132,250,876 - 32,275,330 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl132,251,714 - 32,272,476 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0133,675,744 - 33,697,542 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4130,445,180 - 30,465,942 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera128,286,050 - 28,306,805 (-)NCBICelera
Cytogenetic Map1p11NCBI
TERT
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3851,253,167 - 1,295,068 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl51,253,147 - 1,295,068 (-)EnsemblGRCh38hg38GRCh38
GRCh3751,253,282 - 1,295,183 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 3651,306,282 - 1,348,162 (-)NCBINCBI36Build 36hg18NCBI36
Build 3451,306,286 - 1,348,159NCBI
Celera51,290,088 - 1,332,097 (-)NCBICelera
Cytogenetic Map5p15.33NCBI
HuRef51,234,692 - 1,275,531 (-)NCBIHuRef
CHM1_151,253,108 - 1,294,322 (-)NCBICHM1_1
T2T-CHM13v2.051,160,074 - 1,202,878 (-)NCBIT2T-CHM13v2.0
Tert
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391373,775,030 - 73,797,962 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1373,775,030 - 73,797,962 (+)EnsemblGRCm39 Ensembl
GRCm381373,626,911 - 73,649,843 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1373,626,911 - 73,649,843 (+)EnsemblGRCm38mm10GRCm38
MGSCv371373,764,449 - 73,786,489 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361374,093,003 - 74,115,043 (+)NCBIMGSCv36mm8
Celera1375,955,877 - 75,977,918 (+)NCBICelera
Cytogenetic Map13C1NCBI
cM Map1340.12NCBI
Tert
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_004955504651,779 - 670,589 (-)EnsemblChiLan1.0
ChiLan1.0NW_004955504649,248 - 669,796 (-)NCBIChiLan1.0ChiLan1.0
TERT
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.151,300,397 - 1,338,241 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl51,300,960 - 1,338,872 (-)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v051,542,217 - 1,586,775 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
TERT
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.13411,288,622 - 11,307,790 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl3411,288,622 - 11,307,951 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha3415,798,490 - 15,817,661 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.03411,189,290 - 11,208,463 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl3411,189,290 - 11,208,512 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.13411,240,107 - 11,259,262 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.03411,219,414 - 11,238,599 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.03411,430,438 - 11,449,614 (+)NCBIUU_Cfam_GSD_1.0
Tert
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024407213244,307,679 - 244,331,058 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936815469,020 - 491,697 (+)EnsemblSpeTri2.0
SpeTri2.0NW_004936815468,987 - 492,666 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
TERT
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1679,258,591 - 79,276,421 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11679,258,591 - 79,276,421 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21685,917,150 - 85,935,085 (+)NCBISscrofa10.2Sscrofa10.2susScr3
TERT
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.141,082,894 - 1,119,373 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl41,083,384 - 1,117,468 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366605435,649,406 - 35,684,819 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Tert
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla 1.0NW_004624751624,569 - 647,198 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Tert
149 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:168
Count of miRNA genes:132
Interacting mature miRNAs:144
Transcripts:ENSRNOT00000022683, ENSRNOT00000034937
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2313053Bss51Bone structure and strength QTL 513.80.0001tibia length (VT:0004357)tibia length (CMO:0000450)1132356093Rat
2313070Bss52Bone structure and strength QTL 524.40.0001body length (VT:0001256)body length (CMO:0000013)1132356093Rat
2313090Bmd69Bone mineral density QTL 694.40.0001tibia mineral mass (VT:1000283)cortical volumetric bone mineral density (CMO:0001730)1132356093Rat
738020Pia8Pristane induced arthritis QTL 84.7joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1165833076Rat
1578650Bmd6Bone mineral density QTL 612.2femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)150910843284926Rat
1578651Bmd7Bone mineral density QTL 714.2femur mineral mass (VT:0010011)cortical volumetric bone mineral density (CMO:0001730)150910843284926Rat
1578669Bss9Bone structure and strength QTL 96.3femur morphology trait (VT:0000559)bone trabecular cross-sectional area (CMO:0002311)150910843284926Rat
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
1600360Mcs16Mammary carcinoma susceptibility QTL 162.4mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1224439043433040Rat
7421626Bp360Blood pressure QTL 3600.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1439328949393289Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
631508Sald1Serum aldosterone level QTL 13.7blood aldosterone amount (VT:0005346)serum aldosterone level (CMO:0000487)1985600154856001Rat
2302038Pia31Pristane induced arthritis QTL 315.50.001blood autoantibody amount (VT:0003725)serum immunoglobulin M-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002111)11099206555992065Rat
1300167Hrtrt2Heart rate QTL 24.35heart pumping trait (VT:2000009)heart rate (CMO:0000002)11148131275088344Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)cortical volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2317755Glom22Glomerulus QTL 223.8urine protein amount (VT:0005160)urine protein level (CMO:0000591)11148148232355910Rat
1578756Iddm22Insulin dependent diabetes mellitus QTL 222.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)11183518156835181Rat
5684998Bss101Bone structure and strength QTL 1013.6tibia strength trait (VT:1000284)tibia ultimate force (CMO:0001734)11543162149361612Rat
5684999Bss102Bone structure and strength QTL 1025.50.00000072tibia strength trait (VT:1000284)tibia stiffness (CMO:0001735)11543162149361612Rat
631494Bp95Blood pressure QTL 95400.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)11620621049268520Rat
634353Rends2Renal damage susceptibility QTL 20.05kidney blood vessel morphology trait (VT:0000530)organ lesion measurement (CMO:0000677)11933357156983283Rat
1558642Prcr2Prostate cancer resistance QTL 24.3prostate integrity trait (VT:0010571)area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio (CMO:0000899)12076315844095856Rat
724520Bp145Blood pressure QTL 1452.10.0024arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)12078482865784828Rat
1357397Bw41Body weight QTL 414.190.0001body mass (VT:0001259)body weight (CMO:0000012)12234064749361612Rat
1357401Bw43Body weight QTL 433.75body mass (VT:0001259)body weight (CMO:0000012)12234064749361612Rat
1357400Bw62Body weight QTL624.05inguinal fat pad mass (VT:0010424)inguinal fat pad weight to body weight ratio (CMO:0001253)12234064767340647Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1331785Rf27Renal function QTL 274.643urine sodium amount (VT:0006274)urine sodium level (CMO:0000129)12887978078430678Rat

Markers in Region
PMC27918P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2129,657,353 - 29,657,717 (+)MAPPERmRatBN7.2
Rnor_6.0132,271,017 - 32,271,380NCBIRnor6.0
Rnor_5.0133,695,885 - 33,696,248UniSTSRnor5.0
RGSC_v3.4130,464,483 - 30,464,846UniSTSRGSC3.4
Celera128,305,346 - 28,305,709UniSTS
Cytogenetic Map1p11UniSTS


Genetic Models
This gene Tert is modified in the following models/strains

Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 3 3 1
Low 3 32 54 38 19 38 74 35 35 11
Below cutoff 11 8 9 5 8

Sequence

Nucleotide Sequences
RefSeq Transcripts NM_053423 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_008758683 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_008758684 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_017589078 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039109992 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039109994 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039109998 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039110003 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XR_005504447 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XR_005504448 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XR_005504449 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XR_589899 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide AC142421 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AJ440965 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AJ440966 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AJ488949 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY539717 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY539718 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY539719 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY539720 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  BK000660 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CH474002 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ021473 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  JACYVU010000009 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

Reference Sequences
RefSeq Acc Id: ENSRNOT00000022683   ⟹   ENSRNOP00000022683
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl129,638,051 - 29,659,561 (-)Ensembl
Rnor_6.0 Ensembl132,251,714 - 32,272,476 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000100559   ⟹   ENSRNOP00000076971
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl129,637,506 - 29,659,561 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000110776   ⟹   ENSRNOP00000086875
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl129,637,506 - 29,659,561 (-)Ensembl
RefSeq Acc Id: NM_053423   ⟹   NP_445875
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,638,051 - 29,658,813 (-)NCBI
Rnor_6.0132,251,714 - 32,272,476 (-)NCBI
Rnor_5.0133,675,744 - 33,697,542 (-)NCBI
RGSC_v3.4130,445,180 - 30,465,942 (-)RGD
Celera128,286,050 - 28,306,805 (-)RGD
Sequence:
RefSeq Acc Id: XM_008758683   ⟹   XP_008756905
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,637,213 - 29,659,060 (-)NCBI
Rnor_6.0132,250,876 - 32,275,330 (-)NCBI
Sequence:
RefSeq Acc Id: XM_017589078   ⟹   XP_017444567
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,637,213 - 29,659,499 (-)NCBI
Rnor_6.0132,250,876 - 32,275,330 (-)NCBI
Sequence:
RefSeq Acc Id: XM_039109992   ⟹   XP_038965920
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,637,213 - 29,658,161 (-)NCBI
RefSeq Acc Id: XM_039109994   ⟹   XP_038965922
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,649,048 - 29,659,503 (-)NCBI
RefSeq Acc Id: XM_039109998   ⟹   XP_038965926
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,650,718 - 29,659,509 (-)NCBI
RefSeq Acc Id: XM_039110003   ⟹   XP_038965931
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,637,213 - 29,652,970 (-)NCBI
RefSeq Acc Id: XR_005504447
RefSeq Status:
Type: NON-CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,638,978 - 29,659,503 (-)NCBI
RefSeq Acc Id: XR_005504448
RefSeq Status:
Type: NON-CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,638,051 - 29,659,501 (-)NCBI
RefSeq Acc Id: XR_005504449
RefSeq Status:
Type: NON-CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2129,638,051 - 29,659,501 (-)NCBI
Reference Sequences
RefSeq Acc Id: NP_445875   ⟸   NM_053423
- UniProtKB: Q80SU5 (UniProtKB/Swiss-Prot),   Q673L6 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: XP_008756905   ⟸   XM_008758683
- Peptide Label: isoform X1
- Sequence:
RefSeq Acc Id: XP_017444567   ⟸   XM_017589078
- Peptide Label: isoform X2
- Sequence:
RefSeq Acc Id: ENSRNOP00000022683   ⟸   ENSRNOT00000022683
RefSeq Acc Id: XP_038965920   ⟸   XM_039109992
- Peptide Label: isoform X3
RefSeq Acc Id: XP_038965931   ⟸   XM_039110003
- Peptide Label: isoform X6
RefSeq Acc Id: XP_038965922   ⟸   XM_039109994
- Peptide Label: isoform X4
RefSeq Acc Id: XP_038965926   ⟸   XM_039109998
- Peptide Label: isoform X5
RefSeq Acc Id: ENSRNOP00000086875   ⟸   ENSRNOT00000110776
RefSeq Acc Id: ENSRNOP00000076971   ⟸   ENSRNOT00000100559
Protein Domains
Reverse transcriptase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q673L6-F1-model_v2 AlphaFold Q673L6 1-1125 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:70494 AgrOrtholog
BioCyc Gene G2FUF-61926 BioCyc
Ensembl Genes ENSRNOG00000025327 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000022683 UniProtKB/Swiss-Prot
  ENSRNOP00000076971 ENTREZGENE, UniProtKB/Swiss-Prot
  ENSRNOP00000086875 ENTREZGENE
  ENSRNOP00000086875.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000022683 ENTREZGENE, UniProtKB/Swiss-Prot
  ENSRNOT00000100559 ENTREZGENE, UniProtKB/Swiss-Prot
  ENSRNOT00000110776 ENTREZGENE
  ENSRNOT00000110776.1 UniProtKB/TrEMBL
InterPro DNA/RNA_pol_sf UniProtKB/Swiss-Prot
  RT_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Telomerase_RBD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Telomerase_RT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:301965 UniProtKB/Swiss-Prot
NCBI Gene 301965 ENTREZGENE
PANTHER PTHR12066 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam RVT_1 UniProtKB/Swiss-Prot
  Telomerase_RBD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Tert PhenoGen
PRINTS TELOMERASERT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE RT_POL UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART Telomerase_RBD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF56672 UniProtKB/Swiss-Prot
UniProt A0A8I6AEW6_RAT UniProtKB/TrEMBL
  Q673L6 ENTREZGENE
  Q80SU5 ENTREZGENE
  TERT_RAT UniProtKB/Swiss-Prot
UniProt Secondary Q1LZ57 UniProtKB/Swiss-Prot
  Q4U0V7 UniProtKB/Swiss-Prot
  Q673L3 UniProtKB/Swiss-Prot
  Q673L5 UniProtKB/Swiss-Prot
  Q80SU5 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Tert  telomerase reverse transcriptase      Symbol and Name status set to approved 1299863 APPROVED
2002-06-10 Tert  telomerase reverse transcriptase      Symbol and Name status set to provisional 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_cellular_localization located in cytoplasm early in cell proliferation, then accumulates in nucleus in log phase of growth 70485
gene_function reverse transcriptase component of telomerase 70485
gene_process may regulate telomerase activity in cancer cells 70485
gene_regulation activated by phosphorylation due to H7-sensitive kinases 70485